Cyber Attacks: Why Biotech, Life Sciences & Healthcare organisations fall victim to cybercrime & what you can do about it
16 September 2019 Our industry is under attack – there is no doubt about it! The news of yet another organization falling victim to cybercrime has become a daily occurrence. As long as there is a promise of…
DEP® irinotecan synergistic with Lynparza® in refractory human colon cancer model
12 September 2019 Melbourne, Australia: Starpharma today announced that its patented clinical stage nanoparticle formulation, DEP® irinotecan, showed significantly enhanced efficacy benefits over standard irinotecan (Camptosar®) and olaparib (Lynparza®) alone and in combination, in an irinotecan-refractory HT-29 human colon cancer…
Clarity Pharmaceuticals Announces Submission of Orphan Drug Designation Application for 64Cu-SARTATE™
11 September 2019 Sydney, Australia – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has submitted an Orphan Drug Designation (ODD) request with the U.S. Food and Drug…
New research led by Burnet Institute utilises novel virus-like particles for malaria vaccine development
11 September 2019 New research led by Burnet Institute has demonstrated the effective use of a novel virus-like particles (VLPs) platform for malaria vaccines. The study, published in the international journal PLOS ONE, utilised a novel technology co-developed…
Medtronic Launches New Way to Stimulate Medical Technology Innovation in ANZ
11 September 2019 Medtronic seeks partnership with innovating physicians in Australia and New Zealand to improve healthcare. Sydney, Australia – 11 September 2019 – Medtronic Australasia today launched Medtronic Eureka, a web-based portal for medical technology innovation designed…
Opthea Presents Positive Data from Wet AMD Trial at EURETINA
6 September 2019 Melbourne, Australia; – Opthea Limited (ASX:OPT), a clinical biopharmaceutical company developing novel biologic therapies for eye diseases, announced today that new clinical data from its completed 366 patient Phase 2b randomised, controlled study of OPT-302…
The Social Costs of Delaying Effective Cancer Treatment Using CAR-T Immunotherapy
5 September 2019 CAR-T therapy can save lives and boost benefits to society … if it’s delivered promptly, says Cartherics CEO and Executive Director, Alan Trounson Using the tools of biotechnology and immunology to help transforming cancer from…
Companies urged to help with information on RDTI
3 September 2019 AusBiotech is commissioning research to quantify the additionality and spill-over effects of the R&D Tax Incentive (RDTI) and urgently calls on companies to help with information. Full article here.
Australia’s National Digital Health Survey is open!
3 September 2019 Together we can transform the digital health sector in Australia; simply click the button below As Australia’s only dedicated provider of digital health commercialisation support, ANDHealth is seeking input from digital health innovators and companies…
GTG New Board Appointment
2 September 2019 Genetic Technologies is pleased to announce the appointment of Nick Burrows as Non-Executive Director to the board. Mr Burrows is a contemporary independent Non-Executive Director across the Listed, Government and Private sectors with significant expertise…
FDA provides guidance on clinical pathway to marketing application for Revascor in end-stage heart failure patients with an LVAD
Melbourne Australia; 27 August 2019, and New York, USA, 26 August 2019 Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in cellular medicines for inflammatory diseases, announced today positive outcomes from its recent meeting with the United States Food and…
IDT Secures its first Medicinal Cannabis Manufacturing Permit from the Office of Drug Control
27 August 2019 IDT Australia Limited (ASX: IDT) is pleased to announce that the Department of Health – Office of Drug Control has granted the Company its first Medicinal Cannabis Manufacturing Permit under the Narcotic Drugs Act 1967.…
